Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

BACKGROUND: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited. OBJECTIV...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Respiration
Autori principali: Brunnemer, Eva, Wälscher, Julia, Tenenbaum, Svenja, Hausmanns, Julia, Schulze, Karen, Seiter, Marianne, Heussel, Claus Peter, Warth, Arne, Herth, Felix J.F., Kreuter, Michael
Natura: Artigo
Lingua:Inglês
Pubblicazione: S. Karger AG 2018
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5985741/
https://ncbi.nlm.nih.gov/pubmed/29490307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000485933
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi